Introduction
Mast cells (MCs) initiate inflammatory responses to infectious organisms and allergens. In allergic diseases, MCs are activated by cross-linkage of their high-affinity Fc receptors for immunoglobulin (Ig)E (Fc RI), releasing pre-formed proteases and biogenic amines, and generating leukotriene C 4 (LTC 4 ), the parent molecule of the cysteinyl leukotrienes (cysLTs), and prostaglandin (PG) D 2 (1-3). Aspirin-exacerbated respiratory disease (AERD) is characterized by nasal polyposis, asthma, and MC activation in response to challenge with nonselective inhibitors of cyclooxygenase (COX) (4, 5) . MC activation follows allergen challenge in the lungs or nose of susceptible individuals, inducing tissue swelling, bronchconstriction, and vascular leakage (earlyphase response, EPR) (6) . In vitro, Fc RI-induced MC activation also initiates transcription through the actions of nuclear factor B (NF-B), nuclear factor of activated T cells (NF-AT) and activator protein-1 (AP-1) transcription factors, resulting in sustained cytokine and chemokine generation (7) . MC activation recruits leukocytes to allergen-challenged tissues, resulting in sustained swelling and inflammation (latephase response, LPR) in a significant proportion of susceptible individuals (8) . Mediator generation by MCs stimulated through toll-like receptors (TLRs) also play an important role in protective innate immunity (9) (10) (11) . Thus whether activated through stimulation of Fc RI, idiosyncratic mechanisms, or pattern recognition receptors, MCs provide eicosanoids and inducible cytokines for inflammatory responses in vivo, benefiting the host in protective immunity, but also potentially inducing exacerbations of allergic diseases.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From PGE 2 , a functionally versatile eicosanoid, acts at four divergent G proteincoupled receptors (GPCRs), termed the EP 1 , EP 2 , EP 3 , and EP 4 receptors (reviewed in 12). PGE 2 can amplify inflammatory gene expression and promote tissue pathology in colon cancer (13) and in mouse models of arthritis (14) . In contrast, PGE 2 strongly suppresses allergic respiratory mucosal inflammation. Inhalation of PGE 2 before allergen challenge prevents both EPR and LPR in asthmatic subjects (15) , and decreases the levels of PGD 2 that are detected in the bronchoalveolar lavage fluid after allergen challenge (16) . In AERD, PGE 2 inhalation prevents bronchconstriction induced by challenge with nonselective COX inhibitors and abrogates the characteristic rise in urinary levels of LTE 4 , the end-product of the cysLTs (5, 17, 18) . Collectively, these observations suggest that PGE 2 inhibits MC activation in the respiratory tract. Although PGE 2 reportedly suppresses mediator release by some MC subtypes in vitro by raising intracellular levels of cyclic adenosine monophosphate (cAMP) (19, 20) , it also enhances mediator release from mouse MCs (21) (22) (23) . The mechanisms and EP receptor subtypes responsible for PGE 2 -mediated inhibition of MC activation are incompletely understood.
We explored the mechanisms and receptors by which PGE 2 modulates activation responses of cord blood-derived human MCs (hMCs). hMCs express EP 2 , EP 3 , and EP 4 receptors, and respond to PGE 2 and receptor-selective analogues with anticipated biochemical signatures and signaling events. In contrast to the results of earlier studies of human lung MCs, PGE 2 does not suppress Fc RI-dependent exocytosis by hMCs.
Rather, PGE 2 causes exocytosis on its own when hMCs are primed with IL-4, a function reflecting EP 3 
Materials and Methods
Reagents PGE 2 , PGD 2 , LTD 4 , the EP 2 /EP 3 dual receptor antagonist AH6809 (EC50 = 50 µM) and the EP 2 receptor selective agonist butaprost (Ki ~ 10 µM) were purchased from Cayman Chemical Co (Ann Arbor, MI). EP 1 , EP 2 , EP 3 , and EP 4 receptor-selective agonists (DI-004, AE1-259-01, AE-248, and AE-329, respectively) and an EP 4 receptorselective antagonist (AE-208) were obtained from Ono Pharmaceuticals (Osaka, Japan). These agonists are potent (Ki ~ 3 nM, 150 nM, 7.5 nM and 10 nM for AE1-259-01, DI-004, AE-248, and AE-329, respectively) and reportedly show little to no crossreactivity on cloned EP receptors even at doses 1000 times their Ki values (26, 27) . In primary cells, agonist doses between 0.1 and 10 µM are reportedly sufficient to elicit maximal functional and signaling responses using these agonists (28, 29) . Each selective reagent was dissolved in dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO).
Pertussis toxin (PTX) was purchased from Sigma. The selective agonist of exchange protein activated by cAMP (Epac), 8-pCPT-2'-O-Me-cAMP, and an inhibitor of glycogen synthase kinase 3 (GSK-3) (GSK-3 inhibitor II) were purchased from Calbiochem. A second GSK-3 inhibitor, SB216763, was obtained from Sigma. Inhibitors of PKA (H89, Sigma) and MEK/ERK (UO126, Promega) were used at their recommended concentrations (10 µM and 5 µg/ml, respectively).
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
8
Derivation and priming of hMCs hMCs were derived from cord blood mononuclear cells cultured in the presence of SCF (100 ng/ml), IL-6 (50 ng/ml), and IL-10 (10 ng/ml) (all from R&D, Minneapolis, MN), as previously described (30), and studied when they reached > 95% purity based on staining with toluidine blue (6-9 wk). For FcMRI-dependent exocytosis, cytokine generation, and eicosanoid production, hMCs were transferred to new medium containing SCF and IL-4 (10 ng/ml, R&D) for 5 d before activation (31,32). Because IL-4 did not alter the expression level of any EP receptor and did not change calcium fluxes in response to PGE 2 , signaling studies were performed with unprimed hMCs. Each donor's cells were used for one experiment per assay.
Flow cytometry
Expression of EP receptor proteins was assessed on fixed, permeabilized hMCs as described (33). Polyclonal Abs against each EP receptor (Cayman) and a monoclonal Ab against Kit (Pharmingen) were used at 2 µg/sample. The EP 3 receptor Ab was raised against a peptide sequence (amino acids 308-327) common to all isoforms of this receptor.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from hMCs at 6-8 wk of culture with TRI Reagent h treatment with 100 ng/ml) and the ability of EP receptor-selective agonists to elicit this response were tested with Fura-2 AM (Molecular Probes, Inc., Eugene, OR)-loaded hMCs using a fluorescence spectrophotometer (Hitachi F-4500) using excitation at 340 and 380 nm to monitor cytosolic free Ca For cytokine generation, sensitized, primed hMCs were challenged with Staphylococcus aureus peptidoglycan (PGN) (10 µg/ml, Sigma), anti-IgE (1 µg/ml), or medium alone in the presence or absence of agonists or controls as described for eicosanoids.
Supernatants were collected at 6 h and frozen at -70°C until further analysis with ELISAs for TNF-and IL-5 (both from eBiosiences). The data for each experiment were tabulated as the mean values from triplicate samples. 
SDS-PAGE immunoblotting
Samples of 2 x 10 5 hMCs were stimulated for various intervals with each agonist. Reactions were stopped on ice and the cells were lysed in a buffer containing 1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 5 Rg/ml leupeptin, and 1 Rg/ml pepstatin in 10 mM Tris (pH 8.0). Western blotting was performed as previously described (25) . Dilutions (1:2000) of primary antibodies specific for the active, phosphorylated forms of ERK-1/ERK-2, c-Jun NH 2 -terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) were used.
The same blots were stripped and probed again with rabbit polyclonal antibodies that detect total ERK-1/ERK-2, p38, and JNK at dilutions of 1:2,000. All anti-MAPK antibodies were purchased from Cell Signaling Technologies. ICER was detected with a rabbit polyclonal antiserum that recognizes all forms of cAMP response element modulator (CREM), including ICER (provided by Dr. Carlos Molina, University of New Jersey Medical School) at a concentration of 1:5000 (38).
Real-Time PCR
Samples of 5-10 x 10 6 primed, sensitized hMCs were stimulated for 2 h with antiIgE or medium alone, all in the presence of SCF at a constant concentration of 100 ng/ml, with or without PGE 2 . The expression of TNF-mRNA was determined with realtime PCR performed on ABI PRISM 7700 TM Sequence Detection System (Applied Biosystems, Foster City, CA) as previously described (25) . Primers and probes for the amplification of TNF-and human 2 microglobulin and the corresponding VIC TM dye were purchased from Applied Biosystems.
Statistics
Data are expressed as mean ± SEM from at least three experiments except where otherwise indicated. Because quantities of eicosanoids and cytokines generated by hMCs from different donors varied widely, the data for some analyses were converted to percentages of the control (the samples not treated with PGE 2 or EP receptor-selective agonists). Differences between treatment groups were determined with the student's T test, with P < 0.05 considered significant. A Q test was used to eliminate outlying experiments.
Results

Expression and function of EP receptors
We used RT-PCR to determine the profile of EP receptor mRNAs expressed by hMCs. Bands corresponding to the predicted sizes of the EP 2 and EP 4 receptors were detected in mRNA samples from all 8 donors tested (as shown for one donor, Fig. 1A ).
All 8 donors showed both the EP 3 -II splice variant and at least one Gi-linked EP 3 variant (5 showed EP 3 -I, 4 showed the EP 3 -IV, 4 showed EP 3 -VI, and none showed EP 3 -V transcript). EP 1 receptor transcripts were detected in the RNA from the cells of only one donor (not shown). All of the primer sets yielded bands of the expected sizes from the positive control DNA template, and no products were detected from the negative control template (Fig. 1) . The EP 2 , EP 3 , and EP 4 receptor proteins were all detected by flow cytometry (n = 3, as shown for one experiment, Fig. 1B ), while the EP 1 receptor protein was not detected in the cells from any of these donors. IL-4 priming of the hMCs did not alter the profile or the level of EP receptor mRNA or proteins expressed (not shown).
Virtually all of the cells showed high level cytofluorographic expression of Kit (Fig. 1B) , confirming the identity of the EP receptor-positive cells as hMCs.
In a FLIPR assay, PGE 2 (0.1-10 µM), but not PGD 2 , induced a calcium flux (an expected signature of both EP 1 and EP 3 receptors) ( Fig. 2A) . Subsequently, fluorescence spectrophotometry was used to measure calcium flux in hMCs following treatment with or without PTX. The cells from 8 donors were tested in this assay, and 3 exhibited calcium flux to PGE 2 (1-10 µM); this flux was completely blocked by treatment of the cells with PTX (Fig. 2B) . LTD 4 -mediated calcium flux occurred in every donor and (Fig. 3B) . cAMP values in cell samples stimulated with AE-248 at 10 µM tended to be higher than controls, but did not reach significance (P = 0.08 relative to unstimulated controls, n = 5). The EP 1 receptor-selective agonist D1-004 was inactive (n = 3, not shown). Even at the highest doses tested, none of the selective agonists stimulated as much cAMP accumulation as PGE 2 blocked cAMP accumulation in response to 1 and 10 µM PGE 2 by 69 ± 6 and 42 ± 16%, respectively, but failed to block cAMP accumulation in response to AE-329 (mean ± ½ range, n = 2, data not shown). PTX pre-treatment failed to alter cAMP accumulation in response to any agonist (not shown).
Effects of PGE 2 on exocytosis and eicosanoid production
PGE 2 at doses as high as 10 µM failed to attenuate Fc RI-dependent or PGNdependent exocytosis of -hexosaminidase by IL-4-primed hMCs and tended to induce some exocytosis by itself under these conditions (Fig. 4A) . To determine whether this unanticipated response depended on IL-4, we tested PGE 2 -mediated exocytosis in both IL-4-primed and unprimed cells. PGE 2 induced exocytosis only in the IL-4-primed cells, and this response was blocked by pre-treatment of the cells with PTX (Fig. 4B) . 
Stimulation of the primed hMCs with the EP 3 receptor-selective agonist AE-248 caused
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Cytokine Generation and ICER induction
Primed hMCs generated IL-5 and TNF-V when stimulated with either anti-IgE or PGN. PGE 2 interfered with the production of each cytokine in a dose-dependent manner (as shown in a representative experiment, Fig, 6A ), in response to both anti-IgE and to PGN (Fig. 6B) . AH6809 (50 µM) and AE-208 (10 µM) reversed the inhibitory effect of PGE 2 on TNF-generation by 24 and 50%, respectively (n = 1, not shown). AE1-259-01 inhibited TNF-generation by hMCs in a dose-dependent manner, being statistically significant at 10 µM (n = 3, Fig. 6C ). Butaprost was also active for this function at 10 µM (n = 2, not shown). Both AE-248 and AE-329 also inhibited TNF-production by hMCs (Fig. 6C) . H89 failed to reverse the inhibitory effect of any agonist on cytokine generation (n = 3, not shown). PGE 2 at 10 µM strongly inhibited the Fc RI-induced steady-state expression of TNF-mRNA, as determined by real-time PCR (n = 2); this effect was reproduced by both AE1-259-01 and AE-329 (as shown for one experiment, Fig. 6D ). Pre-treatment of the cells with the selective Epac agonist 8-pCPT-2'-O-MecAMP (10 µM) modestly inhibited Fc RI-mediated TNF-generation (43% inhibition), but had no effect on IL-5 production, and two inhibitors of GSK-3 (GSK-3 inhibitor II (20 µM) and SB 216763 (20 µM) had no effect on TNF generation (14 and 12% inhibition, respectively, not shown).
At 0.1-10 µM, PGE 2 dose-dependently induced ICER expression (Fig. 7A ), peaking at 2-3 h after stimulation (Fig. 1B) . This effect was partly mimicked by stimulation of the cells with forskolin at 200 µM (Fig. 7D) . AE1-259-01 and AE-329 both also induced ICER expression at 1 µM (Fig. 7B, 7D ), while the EP 3 receptor-selective receptors being more potent. We detected both of these receptors at the protein and mRNA levels (Fig. 1) , and showed that both were functional based on the cAMP accumulation induced by the selective agonists AE1-259-01 and AE-329 (Fig. 3) . The complete blockade of AE-329-induced cAMP accumulation by the EP 4 receptor antagonist AE-208 (Fig. 3C) confirmed the specificity of this agonist at 10 µM, and the functionality of the receptor. However, the failure of AE-208 to significantly suppress PGE 2 -induced cAMP stimulation suggests a more dominant role for EP 2 (26, 27) , none of the selective agonists, alone or in various combinations, approached the efficacy of PGE 2 itself. We speculate that primary cells that express comparatively low levels of individual EP receptor proteins (Fig. 1) may require the assembly of ligand-induced, hetero-oligomeric complexes between different EP receptors to amplify PGE 2-dependent signaling events, as reported for other co-expressed GPCRs (43). Such complexes may not be efficiently induced by the selective agonists. We also cannot exclude the potential existence of previously unrecognized EP receptors among the orphan GPCRs.
Splice variants of the human EP 3 receptor mRNA produce multiple isoforms with identical ligand binding properties but different C-termini that confer the ability to either stimulate PTX-sensitive Gi proteins (all isoforms) or Gs proteins (EP 3 -II and EP 3 -IV isoforms) (35,36), mediating opposing effects on adenyly cyclase/cAMP (44,45). The consistent expression of the EP 3 -II message with a combination of Gi-linked variants suggests that the EP 3 receptor protein expressed by hMCs (Fig. 1B) reflects more than one isoform. The modest increment in cAMP that was induced by AE-248 (Fig. 3) suggests the function of the EP 3 -II receptor, although this effect did not reach statistical significance and only occurred at a dose potentially capable of crossover effects (27) .
Since cAMP elevation attenuates calcium signaling (45), concomitant Gs-induced signaling from EP 3 -II or other receptors may explain why EP 3 receptor-dependent calcium flux was observed in only 3 of the 8 donors tested (Fig. 2) (Fig. 2) , reflecting a robust signal through the Gi-linked EP 3 receptor variants responsible for the secretory events observed (Fig. 4, 5) .
For mediator release, we primed hMCs with IL-4 since this cytokine augments both exocytosis and eicosanoid generation (32,47). While earlier studies reported that PGE 2 (by raising cAMP levels) inhibited Fc RI-dependent exocytosis and eicosanoid release from MCs (20, 21) , other studies reported that PGE 2 potentiates histamine release (22) and IL-6 production (23) by mBMMCs through effects at the Gi-linked EP 3 receptor. Despite raising cAMP, PGE 2 did not inhibit Fc RI-dependent exocytosis, instead inducing some exocytosis by itself (Fig. 4A ). This response required IL-4, was blocked by PTX pre-treatment (Fig. 4B) , and was partly mimicked only by AE-248. IL-4 may thus alter the coupling of Gi-linked EP 3 receptor signaling to exocytosis, presumably distal to phospholipase C, inositol phosphate production, protein kinase C activation, and calcium flux since priming was not required for the latter event (Fig. 1). IL-4, which is abundant in allergic inflammation, could promote MC activation responses to PGE 2 in tissues where MCs express EP 3 receptors. 
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was not surprising that pre-treatment of the cells with PGE 2 (or with the EP 2 receptorselective antagonist AE1-259-01) attenuated Fc RI-mediated generation of both PGD 2 and cysLTs (Fig. 5A, 5B) . Unexpectedly, hMCs stimulated with PGE 2 also generated PGD 2 , but not LTC 4 (reflected by the cysLT-specific ELISA). cAMP-dependent PKA phosphorylates 5-LO, preventing its translocation to the nuclear envelope to synthesize the LT precursor LTA 4 (49). This likely explains why cysLT generation occurred in response to PGE 2 when PKA was inhibited by H89 (Fig. 5C ). This response was also TNF-localizes to MCs in airway biopsy specimens from patients with severe asthma who respond therapeutically to TNF--selective antagonists (51) and promotes granulocyte influx in MC-dependent innate immune responses in mice (11) . In our previous studies, adenine nucleotides suppressed TNF-generation by hMCs (25) (Fig. 6 ) suggested a process involving ICER. Indeed, PGE 2 strongly induced ICER expression (Fig. 7) , as did the adenylyl cyclase activator forskolin. Importantly, this response likely involved input from more than one EP receptor, since both AE1-259-01 and AE-329 both induced ICER on their own at 1 µM (Fig. 7B, 7D) . Moreover, H89 (10 µM) only partly blocked ICER induction, but completely blocked it when used in combination with UO126 (Fig. 7C, 7D ). Thus PKA receptor-dependent MC activation is reported to occur in the skin in a mouse model of cutaneous inflammation (21) , and this may reflect both the release of histamine and PGD 2 . It seems likely that the pro-and anti-MC activating effects of PGE 2 reported for respectively for skin (21) and lung (15) 
